WGS

The past six months have seen significant volatility and negative impacts on GeneDx Holdings Corp.'s stock price. The company reported its first-quarter 2026 financial results, which significantly missed analyst expectations. Following the Q1 2026 results, GeneDx lowered its full-year 2026 revenue guidance by approximately $65 million. The stock price plummeted significantly after the Q1 2026 results were announced. Several law firms have announced investigations into GeneDx Holdings Corp. concerning potential violations of federal securities laws. The company took a $31.3 million non-cash impairment charge related to the goodwill and intangible assets of its Fabric Genomics reporting unit. Over the past 52 weeks, the stock has traded between a low of $32.21 and a high of $170.87.